Vaccine Potential of Ebola Virus VP24, VP30, VP35, and VP40 Proteins
- 1 August 2001
- Vol. 286 (2) , 384-390
- https://doi.org/10.1006/viro.2001.1012
Abstract
No abstract availableKeywords
This publication has 25 references indexed in Scilit:
- The Ebola virus VP35 protein functions as a type I IFN antagonistProceedings of the National Academy of Sciences, 2000
- Crystal structure of the matrix protein VP40 from Ebola virusThe EMBO Journal, 2000
- Recombinant RNA replicons derived from attenuated Venezuelan equine encephalitis virus protect guinea pigs and mice from Ebola hemorrhagic fever virusVaccine, 2000
- Role of Dendritic Cell Targeting in Venezuelan Equine Encephalitis Virus PathogenesisJournal of Virology, 2000
- The Reemergence of Ebola Hemorrhagic Fever, Democratic Republic of the Congo, 1995The Journal of Infectious Diseases, 1999
- A Mouse Model for Evaluation of Prophylaxis and Therapy of Ebola Hemorrhagic FeverThe Journal of Infectious Diseases, 1998
- Antigenicity and Vaccine Potential of Marburg Virus Glycoprotein Expressed by Baculovirus RecombinantsVirology, 1997
- Descriptive analysis of Ebola virus proteinsVirology, 1985
- Plaque Assay for Ebola VirusJournal of Clinical Microbiology, 1981
- ISOLATION AND PARTIAL CHARACTERISATION OF A NEW VIRUS CAUSING ACUTE HÆMORRHAGIC FEVER IN ZAIREPublished by Elsevier ,1977